Technology
AI-designed vaccine completes first human trial
Synthesized from1 source
AI-generated summary
AI-designed vaccine completes first human trial
A vaccine component developed entirely by artificial intelligence has been trialled in 39 people, the first such human study.
- The AI designed a "super-antigen" targeting all coronaviruses, including Covid variants and potential animal-to-human viruses.
- The trial results, published in the Journal of Infection, showed a "modest" immune response, according to the researchers.
- A second trial with approximately 200 participants is planned to further assess the vaccine's ability to train the immune system.
- The Cambridge team is also developing AI-designed vaccines for flu, Ebola, and H5N1 bird flu.
TopicsArtificial IntelligenceVaccineCOVID-19EbolaH5N1 Bird FluClinical trialsCambridge UniversityFlu
Coverage
1 outlet — read the original reporting
Every story is brought together from multiple sources into a single, clear summary — with every perspective kept, not flattened.